Linked Life Data

20492877

Source:http://linkedlifedata.com/resource/pubmed/id/20492877

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-5-24
pubmed:abstractText
Psoriatic arthritis (PA) is a chronic inflammatory condition whose symptoms generally appear after the skin symptoms. Making an early diagnosis and treatment of the disease is of vital importance because of the potential development of mutilating and deforming arthritis. Classical treatments of PA include the use of non-steroid anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARD) such as methotrexate, sulfasalazine, or gold, and finally, leflunomide. Research on the pathophysiology of psoriasis and of the PA has led to the incorporation of biological treatments, specifically anti-TNF drugs. The three treatments used most in PA are etanercept, infliximab and adalimumab. Of all these, we are going to make a systematic review of the principal studies available on etanercept for the treatment of PA.
pubmed:language
spa
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1578-2190
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
101 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
26-34
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Psoriatic arthritis and etanercept].
pubmed:affiliation
Servicio de Dermatología, Hospital Clínico San Carlos, Madrid, España. javierpedraz@aedv.es
pubmed:publicationType
Journal Article, English Abstract, Review, Case Reports